Attendees:

**Board Members:** Marie-Paule Kieny (Chair), Charles Clift (Vice-Chair), Manica Balasegaram, Anna Zakowicz, Anban Pillay, Patrizia Carlevaro, Brian Tempest, Claudia Chamas and Jayashree Watal.

**MPP Staff:** Charles Gore (Executive Director), Asma Rehan (Operations Manager), Chan Park (General Counsel), Maica Trabanco (Associate Counsel), Andrew Goldman (Associate Counsel) and Sandra Nobre (Business Development Director)

The Governance Board of the Medicines Patent Pool (MPP) thanks the Expert Advisory Group (EAG) for its report assessing the final results of negotiations between the MPP and AbbVie on a licence agreement for glecaprevir/pibrentasvir (G/P). The Board has reviewed the EAG report and the proposed Licence Agreement between the MPP and AbbVie. The Board agrees with the EAG's assessment that the proposed collaboration is consistent with the MPP’s mandate as defined in its Statutes and Memorandum of Understanding with Unitaid, and represents a significant improvement over the status quo.

Therefore, the Board requests the Executive Director to finalise and sign the necessary documents with AbbVie to formalize the collaboration. The Board further recommends that the MPP continue to seek the inclusion of all people living with HCV in low- and middle-income countries in this and other future collaborations.